Bosentan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and PHARMAC (New Zealand) recommended or restricted bosentan, while AWMSG (Wales) and CIPM (Spain) did not recommend it.
The file has been open for more than a decade: 23.2 years separate the first record, 5 Feb 2003 at HAS (France), from the most recent, 20 May 2026 at CIPM (Spain).
No assessment is on file from TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for bosentan, 1 submission was never made — an outcome set by the company rather than the assessor.
3 distinct indication wordings are recorded for bosentan by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 21 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess bosentan, on 5 Feb 2003; CIPM (Spain) did not open a file until 20 May 2026 — an unusually long tail of 23.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 11 years in total.
4 of the 6 agencies here assessed bosentan more than once, HAS (France) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for bosentan.
The full ledger for bosentan reads 15 recommended, 3 not recommended, 2 other and 1 non-submission.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Mar 2018 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| PBAC (Australia) | 2015 | Pulmonary Arterial Hypertension (PAH) | The PBAC considered that progression of disease in patients on PAH agents does not necessa… | source |
| PHARMAC (New Zealand) | 14 Feb 2013 | Pulmonary artery hypertension - paediatric patients | PTAC advice: Recommended alteration to access criteria · decision reached | source |
| AWMSG (Wales) | 1 Sep 2011 | Treatment of class II pulmonary arterial hypertension | not endorsed (non-submission) | source |
| SMC (Scotland) | 10 Nov 2008 | pulmonary arterial hypertension (PAH) WHO functional class II | not recommended | source |
16 further decisions for bosentan, across 5 agencies, are not shown here. They include the most recent record on file, 20 May 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 10 further source documents.
Related molecules
- macitentan — divergent outcome (recommended vs restricted) on a shared indication
- riociguat — same ATC class C02K — Antihypertensives
- ambrisentan — same ATC class C02K — Antihypertensives
- sotatercept — same ATC class C02K — Antihypertensives
- vutrisiran — also decided by CIPM in 2026Q2
- omalizumab — also decided by CIPM in 2026Q2
Coverage: 21 decisions for bosentan from 6 agencies, 2003 to 2026. Data to 7 Sep 2026. ATC class C02K — Antihypertensives. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.